Show simple item record

dc.creatorAlnaaimi M., Sulieman A., Alkhorayef M., Salah H., Alduaij M., Algaily M., Alomair O., Alashban Y., Almohammad H.I., Bradley D., Kappas C.en
dc.date.accessioned2023-01-31T07:31:00Z
dc.date.available2023-01-31T07:31:00Z
dc.date.issued2021
dc.identifier10.1016/j.radphyschem.2021.109668
dc.identifier.issn0969806X
dc.identifier.urihttp://hdl.handle.net/11615/70456
dc.description.abstractThe objective of this study is to assess the patients' effective and organ dose during theranostic applications in Kuwait. In total, eighteen adults' patients were conducted nuclear medicine procedures with 177Lu Dotatate for theranostic purpose in Kuwait Cancer control center (KCCC), Kuwait. Medium energy collimator (MEC) (208 keV Scatter 26% better than 113 keV Scatter 60%) was utilized to obtain scans in definite time intervals ranged from one to 2 h (before voiding), 6:00, 24:00, 48:00, 72:00 h. Patients, tissue and organ radiation doses were computed utilizing OLINDA/EXM Software. The average radiation effective dose (in mSv/MBq) for bladder, liver, and both kidneys (left & right), were 0.36, 0.08, 0.61 & 0.60. The range of the effective dose was from 0.55 mSv to 7.7 mSv. The acquired scans using 177Lu were delivered diagnostic findings. The patients’ effective dose is lower compared to the previous studies. Variation is attributed to the departmental protocol and administered activity. The values of the mean organ dose were comparable and lower than previously published studies. Different organs have different level of doses, which may affected by the presence of the metastatic tumors in the entire organ. © 2021 Elsevier Ltden
dc.language.isoenen
dc.sourceRadiation Physics and Chemistryen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85111288581&doi=10.1016%2fj.radphyschem.2021.109668&partnerID=40&md5=933e446be68a34ee959c4c1ddd0c0f49
dc.subjectDiagnosisen
dc.subjectDosimetryen
dc.subjectRadiationen
dc.subjectRadiologyen
dc.subjectAdult patientsen
dc.subjectCancer controlen
dc.subjectControl centreen
dc.subjectEffective doseen
dc.subjectLu-177en
dc.subjectMedium energyen
dc.subjectOrgan doseen
dc.subjectRadiation risken
dc.subjectTargeted radionuclide therapiesen
dc.subjectTheranosticsen
dc.subjectNuclear medicineen
dc.subjectlutetium 177en
dc.subjectoxodotreotide lutetium lu 177en
dc.subjectprostate specific membrane antigenen
dc.subjectradioisotopeen
dc.subjectadulten
dc.subjectArticleen
dc.subjectbladderen
dc.subjectcancer radiotherapyen
dc.subjectclinical articleen
dc.subjectdigital imaging and communications in medicineen
dc.subjectdosimetryen
dc.subjecteffective dose (radiation)en
dc.subjectfraction absorbeden
dc.subjecthumanen
dc.subjectkidneyen
dc.subjectKuwaiten
dc.subjectliveren
dc.subjectmaleen
dc.subjectprostate canceren
dc.subjectradiation doseen
dc.subjectradiation dose distributionen
dc.subjectradioactivityen
dc.subjectradioisotope therapyen
dc.subjectsingle photon emission computed tomography-computed tomographyen
dc.subjectspleenen
dc.subjectElsevier Ltden
dc.titleOrgans dosimetry in targeted radionuclide therapyen
dc.typejournalArticleen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record